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Abstract
Background: Since 2006, the Peruvian National TB program (NTP) recommends voluntary counseling and testing
(VCT) for all tuberculosis (TB) patients. Responding to the differential burden of both diseases in Peru, TB is
managed in peripheral health facilities while HIV is managed in referral centers. This study aims to determine the
coverage of HIV screening among TB patients and the characteristics of persons not screened.
Methods: From March 2010 to December 2011 we enrolled new smear-positive pulmonary TB adults in 34 health
facilities in a district in Lima. NTP staff offered VCT to all TB patients. Patients with an HIV positive result were
referred for confirmation tests and management. We interviewed patients to collect their demographic and clinical
characteristics and registered if patients opted in or out of the screening.
Results: Of the 1295 enrolled TB patients, nine had a known HIV diagnosis. Of the remaining, 76.1% (979) were screened
for HIV. Among the 23.9% (307) not screened, 38.4% (118) opted out of the screening. TB patients at one of the health
care facilities of the higher areas of the district (OR = 3.38, CI 95% 2.17–5.28 for the highest area and OR = 2.82, CI 95% 1.
78–4.49 for the high area) as well as those reporting illegal drug consumption (OR = 1.65, CI 95% 1.15–2.37) were more
likely not to be screened. Twenty-four were HIV positive (1.9% of all patients 1295, or 2.4% of those screened). Of 15
patients diagnosed with HIV during the TB episode, ten were enrolled in an HIV program. The median time between the
result of the HIV screening and the first consultation at the HIV program was 82 days (IQR, 32–414). The median time
between the result of the HIV screening and antiretroviral initiation was 148.5 days (IQR 32–500).
Conclusions: An acceptable proportion of TB patients were screened for HIV in Lima. Referral systems of HIV positive
patients should be strengthened for timely ART initiation.
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Background
In 2016, 1.3 million people died from tuberculosis (TB)
and 1 million people died from HIV. Of the 10.4 million
people that develop TB each year, one out of ten is HIV
positive [1]. HIV is one of the most important challenges
to TB control globally [2]. By severely affecting the
immune system, HIV facilitates TB dissemination and
increases mortality of coinfected persons as compared to
TB patients who are HIV negative [2, 3]. Active TB is an
AIDS-defining disease and a criterion to start antiretro-
viral therapy (ART); therefore, diagnosis of both diseases
is important in co-infected patients [4–8].
The optimal HIV screening strategy has been debated
since the availability of HIV screening tests in 1985. Ini-
tially, HIV screening was mainly done in blood banks. In
1987, counseling and screening was recommended to
persons at risk of HIV infection such as those with risk
behaviors and those seeking care for sexually transmitted
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infections (STI). In 1993, screening was extended to pa-
tients attending hospitals that reported an HIV preva-
lence above 1% among their patients. In 1995, learning
that zidovudine could prevent HIV vertical transmission
prompted the implementation of universal screening
among pregnant women [9]. Despite these efforts, a low
proportion of persons infected with HIV were aware of
their status, and a high proportion of patients were diag-
nosed in late stages of HIV infection. To increase HIV
diagnosis, a voluntary counseling and testing strategy re-
quired scaling up [10]. In 2005, the Center for Disease
Control (CDC), recommended provider-initiated coun-
seling and testing to all persons between 13 and 64 years
unless the person opts out [9, 11]. The World Health
Organization (WHO) recommends HIV voluntary coun-
seling and testing as a standard practice among TB pa-
tients to increase HIV status awareness [3]. However, in
2016, the WHO estimated that 57% of notified cases of
TB were aware of their HIV status [1].
In Peru, HIV is concentrated among high-risk groups
and 0.4% of the general population is infected, on the
other hand, TB burden is among the highest in the re-
gion: in 2016 the incidence for all TB cases was 117 per
100,000 population [1]. As the burden of TB is higher,
case detection and treatment is conducted in the first
level of health care. Conversely, because of its low preva-
lence, HIV/AIDS is managed in referral centers [12]. TB
nurses working in peripheral health facilities offer volun-
tary counseling and testing for HIV of TB patients rou-
tinely. Peru adopted the HIV voluntary counseling and
testing strategy among TB patients in 2006 [13]. The
WHO reported that of the 31,079 TB patients notified
in 2016, 84% were screened for HIV. Of them, 6% were
HIV positive [14]. TB-HIV co-infection is a challenge for
public health, both for diagnosis and timely management
and for the prognosis of both diseases. It is essential to
expand HIV screening of TB patients and timely initi-
ation of ART to improve individual prognosis, to reduce
HIV transmission and to reduce the burden of HIV and
TB. This study aims to determine the proportion of
newly diagnosed TB patients screened for HIV in a dis-
trict with high TB incidence in Lima, Peru and to
analyze patient’s and health system’s characteristics asso-
ciated to not being screened for HIV.
Methods
Study design and setting
We conducted a secondary data analysis of cross sec-
tional data obtained within a cohort study in 34 health
care facilities (one district hospital and 33 primary care
health centers) managed by the Ministry of Health in
the San Juan de Lurigancho district in Lima, Peru. This
was a cohort study to determine the proportion of drug
resistant TB and the rate of recurrent episodes among
TB patients. A sample size of 1130 was calculated for
those objectives. Adults with a smear-positive pulmonary
TB episode diagnosed between March 2010 and Decem-
ber 2011 with no history of previous TB treatment were
enrolled. Patients initiated anti-TB treatment at the TB
clinic and were followed at the health facility until the
end of their treatment regimen. Treatment outcomes
were prospectively obtained from the NTP registers. TB
registers were monitored monthly up to two years after
the end of treatment of the last enrolled case for TB re-
currence. If a recurrent episode was found among an en-
rolled and cured TB patient, a sputum sample was
collected [15, 16]. San Juan de Lurigancho is a periurban
district in the north east of Lima and lies on the side of
a hill. It is the most populous district in Peru, with over
one million inhabitants. In 2015, TB incidence in Lima
was 164.9 per 100,000 inhabitants [17].
The NTP guidelines recommend that all TB patients
should offered HIV screening with an ELISA or a rapid
test after a pre test counseling session conducted by a
TB nurse trained by the HIV program. A post test coun-
seling session is given in referral health facilities where
HIV multidisciplinary teams provide HIV care [18].
Study participants
The cohort study included consenting adult patients
with a first episode of smear positive pulmonary TB di-
agnosed between March 2010 and December 2011 in
one of the study sites. Patients that had received more
than two doses of TB treatment were excluded. This sec-
ondary data analysis included all cohort participants.
Study procedures
Trained field workers enrolled participants and applied a
structured questionnaire to collect demographic, epi-
demiological and clinical data. The variables sex, age,
weight loss, education, social economical status, marital
status, illegal drug consumption, alcohol abuse, history of
deprivation of liberty, history of diabetes mellitus, employ-
ment and place of birth were obtained through face to
face interviews while smear, culture and drug susceptibil-
ity test (DST) results, treatment outcomes, and HIV test
results were retrieved from clinical files. A single sputum
specimen was collected from each participant at enroll-
ment. Sputa were transported to the Tuberculosis Labora-
tory of the Instituto de Medicina Tropical Alexander von
Humboldt analyzed under smear microscopy and cultured
on Löwenstein-Jensen media. The proportion methods
evaluated drug susceptibility to isoniazid, rifampicin and
ethambutol. Results were reported to the health facility
[15, 16]. The Tuberculosis Laboratory at the Instituto de
Medicina Tropical Alexander von Humboldt conducted
regular quality control assurance procedures for smear
microscopy, culture and DST.
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Study participants that were not yet screened for HIV
by the TB routine staff at the moment of the interview,
were invited for screening. Those agreeing to be screened
received counseling by the Ministry of Health designated
staff and the study field workers drew a sample of blood.
An ELISA or a rapid test was done. If positive, the diagno-
sis of HIV infection requires a confirmatory test (Indirect
Immunofluorescence-IFI or Western Blot). ELISA for
HIV was done at the Instituto de Medicina Tropical
Alexander von Humboldt. Results were given to the TB
staff that delivered the results to patients and managed
them accordingly. Patients with a positive test (either ob-
tained by the Ministry of Health routine procedures or by
the study) were referred to HIV services (in Peru, these
are located in referral hospitals) for a confirmatory test
and post test counseling. If HIV was confirmed they were
enrolled in the Ministry of Health HIV program where
ART is provided free of cost to patients. The criteria to
initiate ART [19] at the time of the study (2010–2011)
were: Any symptomatic HIV-positive person with clinical
stage B or C regardless CD4 count, any HIV-positive per-
son with a CD4 count of 200 cells / mm3 regardless of
clinical stage and other criteria determined by an expert
committee. Clinical files of all TB-HIV positive patients
were reviewed at the end of their TB treatment. We regis-
tered the date in which they were enrolled in the HIV pro-
gram at the referral facility and the date of ART initiation.
For the cohort study logistics, the district was divided
in four geographical areas depending on the altitude re-
lated to the hill of the study district and balancing the
number and size of facilities in each area: highest, high,
middle and lower. A field worker was assigned to each
area. The two higher areas lie by the side of the hill that
is less urbanized with poorer housing quality, and the
middle area and lower areas, are on the flatter and more
urban area of the district.
Data management and analysis
Data were entered in a specially designed database in
Access for Microsoft Office (Microsoft Corporation,
Redmond, WA, US) and analyzed using Epi Info ™ ver-
sion 7.1. The outcome was HIV screening (done or not
done). Patients not screened were further categorized in
“opted out” which included participants that explicitly
opted out of HIV screening by saying “no, I do not want
to be screened” and in “screening not done for unknown
reasons” which included participants that did not expli-
citly opted out, but either HIV screening was not offered
for unknown reasons or despite it being offered, it was
not done for unknown reasons. This categorization
aimed to compare the characteristics of patients opting-
out to those who did not explicitly opted out but screen-
ing not done for diverse reasons (patient may not want
to be screened but does not say so, or he/she may want
but it is not done, because of lack of follow up by the
staff or other reasons). The hypothesis underlying this
subclassification was that TB patients opting out of HIV
screening may have a higher risk of HIV infection and
fear of it makes them opt out. While this hypothesis
cannot be confirmed in this study, a comparison of pa-
tients opting out with those not screened without expli-
citly opting out, could be relevant. Age was categorized
in young adults (18–34 years), adults (35–59 years) and
older adults (60–90 years). The 22-months study period
was divided in four periods to determine time trends in
HIV screening. HIV screening could be different in time
if there were screening tests stock outs, or if staff
changes in time affected performance related to HIV
screening. Socioeconomic status was measured by a
Peruvian Ministry of Finance validated scale and catego-
rized patients in poor (including extreme and not ex-
treme poverty) and not poor [20]. Alcohol consumption
was measured using the validated CAGE four-question
screening test [21]. Those that had a high suspicion of
alcoholism we classified as alcoholics.
We developed contingency tables to compare the inde-
pendent variables with the outcome. Three bivariate
analyses of independent variables and outcomes were
done: being screened versus not being screened, which
included all patients enrolled; refusing screening versus
not being screening for unknown reasons, which in-
cluded patients that were not screened; and HIV positive
versus negative, which included all those screened. Odds
ratios (OR) were calculated with 95% confidence inter-
vals (CI). Two multivariate models were constructed
using logistic regression, one for predictors of being
screened for HIV, and one for predictors of opting out
among those not screened for HIV. Both multivariate
analyses were done in a stepwise backward manner. Var-
iables associated with the outcome at a p < 0.2 signifi-
cance as well as others relevant for each of the two
outcomes were included in the multivariate model. We
excluded missing data in the analysis of the determi-
nants of not being screened for HIV. We included 1197
patients (98 were excluded for missing data: 88 on socio
economic status and 10 for all other independent vari-
ables) in the multivariable model.
Results
Study population and HIV prevalence among TB patients
The cohort study included 1295 patients and all were
included in our analysis. Figure 1 describes the study
population, those screened for HIV and the HIV
screening results. Nine were aware of their HIV posi-
tive status before the TB diagnosis and fifteen were
diagnosed with HIV during the TB episode. HIV
prevalence was 1.9% (24/1295) among all TB patients,
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while it was 2.4% (24/988) among those with a known
HIV status (excluding those not tested).
HIV screening coverage and determinants of screening
Of all HIV screenings conducted among the study par-
ticipants (76.1%, 979/1286): 81.2% (795/979) were done
by the routine TB staff, 18.8% (184/979) were done by
the study field workers. Therefore, if the study staff had
not conducted additional efforts to those of the routine
staff to screen TB patients for HIV, coverage of HIV
screening among new TB patients would have been
61.8% (795/1286). Table 1 describes the characteristics
of patients that were screened, of those opting out and
of those not screened for unknown reasons.
Among those screened for HIV, the median time be-
tween TB treatment initiation and HIV screening was
4 days (interquartile range 0–18 days). In 69.9% (684/979)
patients, HIV screening was done before or within 15 days
after TB treatment initiation -as per NTP guidelines- and
after 15 days of starting TB treatment in 30.1% (295/979)
patients.
Table 2 shows the determinants of not being screened
for HIV of the 1197 patients included in the analysis (98
were excluded for missing data: 88 on socio economic
status and 10 on a single other variable). Receiving TB
care in one of the health care facilities of the higher
areas of the district (odds ratio (OR) = 3.38, confidence
interval (CI) 95% 2.17–5.28, p < 0.0001 for the highest
area and OR = 2.82, CI 95% 1.78–4.49, p < 0001, for the
high area) as well as reporting illicit drug consumption
(OR = 1.65, CI 95% 1.15–2.37, p = 0.0062) was associated
to not being screened for HIV.
Table 3 compares the characteristics of patients opting
out of HIV screening to those of patients not screened
for unknown reasons. Attending a health care facility in
the highest area of the district was associated to opting
out of screening. Patients reporting illegal drug con-
sumption and those enrolled in the third period of the
study were more likely not to be screened because of un-
known reasons as compared to opting out of screening.
Determinants and management of HIV positive TB
patients
In a bivariate analysis of the characteristics of HIV posi-
tivity (including both those diagnosed before the TB epi-
sode and those diagnosed during the TB episode) among
the 988 patients screened, more men than women were
HIV positive (18 (3.0%) vs. 6 (1.5%)), more adults than
young adults (9 (4.3%) vs. and 15 (2.0%)) and more pa-
tients reporting illegal drug consumption were HIV
positive than those reporting never having used illegal
drugs (crude OR: 4.24, 95%CI 1.85–9.73). We had insuf-
ficient power to conduct a multivariate analysis of pre-
dictors of HIV positive status.
Fig. 1 Patients with a first episode of tuberculosis and HIV screening in San Juan de Lurigancho, 2010–2011
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Table 1 Characteristics of patients with a first episode of tuberculosis by their HIV screening status, San Juan de Lurigancho, 2010–2011
Characteristics Screened Not screened for
unknown reasons
Opted out of screening
N (%) N (%) N (%)
Sex
Female 394 (39.9%) 69 (36.3%) 39 (33.1%)
Male 593 (60.1%) 121 (63.7%) 79 (66.9%)
Age, in years
18–34 721 (73.0%) 137 (72.1%) 83 (71.0%)
35–49 210 (21.3%) 41 (21.6%) 24 (20.5%)
> 50 57 (5.7%) 12 (6.3%) 10 (8.5%)
Weight loss reported by the patient
Yes 798 (81.1%) 162 (85.3%) 94 (79.7%)
No 186 (18.9%) 28 (14.7%) 24 (20.3%)
Location of health facility in district area
Lowest area 199 (20.2%) 25 (13.2%) 8 (6.8%)
Middle area 314 (31.8%) 35 (18.4%) 12 (10.2%)
Highest area 259 (26.2%) 73 (38.4%) 63 (53.4%)
High area 215 (21.8%) 57 (30.0%) 35 (29.6%)
Education
Primary school or less 400 (40.6%) 87 (45.8%) 60 (50.8%)
High school 365 (37.0%) 67 (35.3%) 36 (30.6%)
Higher education 221 (22.4%) 36 (18.9%) 22 (18.6%)
Socioeconomic status
Poor 240 (26.0%) 48 (27.3%) 30 (28.3%)
Not poor 685 (74.0%) 128 (72.7%) 76 (71.7%)
Marital status
Married / cohabiting 369 (37.4%) 65 (34.3%) 53 (45.0%)
Divorced 72 (7.3%) 16 (8.4%) 5 (4.2%)
Single 521 (52.8%) 101 (53.1%) 56 (47.5%)
Widow 25 (2.5%) 8 (4.2%) 4 (3.3%)
Illegal drug consumption
No 838 (84.9%) 140 (73.7%) 99 (83.9%)
Yes 149 (15.1%) 50 (26.3%) 19 (16.1%)
Alcohol consumption (CAGE score)
Alcoholism 52 (8.9%) 13 (10.7%) 7 (9.3%)
No alcoholism 534 (91.1%) 109 (89.3%) 68 (90.7%)
Ex prison inmate
Yes 49 (5.0%) 8 (4.2%) 4 (3.4%)
No 936 (95.0%) 182 (95.8%) 114 (96.6%)
Diabetes mellitus, as reported by the patient
Yes 41 (4.2%) 9 (4.7%) 5 (4.2%)
No 944 (95.8%) 181 (95.3%) 113 (95.8%)
Type of TB treatment regimen
Regimen for drug sensitive TB 970 (98.3%) 189 (99.5%) 116 (98.3%)
Regimens for drug resistant TB 17 (1.7%) 1 (0.5%) 2 (1.7%)
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Of the nine patients known to be HIV positive before
the TB episode, eight were already on ART. Of the 15
patients diagnosed with HIV during the TB episode, we
found evidence that 10 were affiliated to the Ministry of
Health HIV program at a referral hospital and 9 were
started on ART. We did not find evidence of HIV pro-
gram enrollment in five patients. These patients may
have been enrolled in an HIV program without it being
registered in their TB clinical files, they may have
attended a private HIV care facility where they have to
pay for care and ART, or they may have not been en-
rolled in an HIV program. The median time between the
result of the HIV screening and the first medical consult-
ation of the HIV program, among those 10 patients, was
82 days (IQR, 32–414). The median time between the
result of the HIV screening and ART initiation was
148.5 days (IQR, 32–500). The median CD4 cell count
among patients enrolled in HIV care during the TB epi-
sode was 189 cells/mm3 (IQR, 55–312).
Discussion
We found an HIV screening coverage of 76.1% among
patients recently diagnosed with smear positive pulmon-
ary TB in an urban context of median TB incidence and
low HIV prevalence. Factors associated to not being
screened were illegal drug consumption and geograph-
ical location of the TB health facility within the study
district. Fifteen TB patients were diagnosed with HIV
during the TB episode, of which five did not have evi-
dence of HIV program enrollment upon completion of
TB treatment.
In the Americas region, in 2016, 80% persons notified
for TB had a documented HIV positive test result, which
is above the global proportion for 2016 (57%). In the
same year, HIV screening in Peru covered 84% of TB pa-
tients [14]. In 2010 (when our study was conducted) the
National TB Program reported that 76% of TB patients
were screened for HIV [22]. In our study, conducted be-
tween 2010 and 2011, we found a fairly high coverage,
however, the study staff did additional efforts to screen
those that had not being initially screened.
Only 9.2% TB patients opted out of screening, while
14.7% were not screened for unknown reasons. Patients
not screened without explicitly opting out may have not
wanted to be screened but did not say so, or the screen-
ing may have been delayed or postponed for diverse rea-
sons (patient’s reasons such as not being sure, or fearing
HIV screening, or health system reasons such as inad-
equate follow up of screening request). In South Africa,
voluntary counseling and testing was adopted in 2007
but less than half of the TB patient’s accepted HIV
screening [23]. In India, 60% of TB patients were
screened for HIV and 33% of new HIV diagnoses would
have been missed if screening during the TB episode
were not done [24].
Our finding that living in the higher areas of the dis-
trict that lie by the hill as opposed to living in the mid-
dle and lower areas that are more urbanized, was
associated to not being screened. Also, those living in
the highest area were more likely to opt out of screening.
This may be due to the fact that in higher areas of the
district there are fewer health centers and road access
may be more difficult. This area of the district has lower
socioeconomic status, however, the association we found
was independent of that factor and of level of education
of the patient. This suggests that health care facility-
related factors not measured in this study could be asso-
ciated to screening coverage. Management of health
Table 1 Characteristics of patients with a first episode of tuberculosis by their HIV screening status, San Juan de Lurigancho, 2010–2011
(Continued)
Characteristics Screened Not screened for
unknown reasons
Opted out of screening
Employment
Yes 695 (70.4%) 138 (72.6%) 83 (70.3%)
No 190 (19.3%) 40 (21.1%) 21 (17.8%)
Student 102 (10.3%) 12 (6.3%) 14 (11.9%)
Study period
1 261 (26.4%) 39 (20.5%) 34 (28.8%)
2 233 (23.6%) 42 (22.1%) 28 (23.7%)
3 258 (26.2%) 64 (33.7%) 18 (15.3%)
4 235 (23.8%) 45 (23.7%) 38 (32.2%)
Place of birth
Coastal region 611 (62.0%) 116 (61.1%) 74 (62.7%)
Jungle region 138 (14.0%) 27 (14.2%) 19 (16.1%)
Andean region 237 (24.0%) 47 (24.7%) 25 (21.2%)
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Table 2 Determinants of not being screened for HIV among 1197 patients with a first episode of smear positive pulmonary
tuberculosis, San Juan de Lurigancho, 2010–2011
Characteristics Screened
N(%)
Not screened
N(%)
Crude OR (95% CI) p Adjusted OR (95%CI) p
Sex
Female 394 (78.5%) 108 (21.5%) 1
Male 593 (74.8%) 200 (25.2%) 1.23 (0.94–1.63) 0.136
Age, in years
18–34 721 (76.6%) 220 (23.4%) 0.94 (0.68–1.31) 0.752
35–49 210 (76.4%) 65 (23.6%) 1
> 50 57 (72.1%) 22 (27.9%) 1.15 (0.63–2.09)
Weight loss reported
by the patient
Yes 798 (75.7%) 256 (24.3%) 1.07 (0.76–1.51) 0.699
No 186 (78.2%) 52 (21.8%) 1
Location of health
facility in district area
Lowest area 199 (85.8%) 33 (14.2%) 1 1
Middle area 314 (87.0%) 47 (13.0%) 0.89 (0.54–1.47) 0.90 (0.54–1.49) < 0.001
Highest area 259 (65.6%) 136 (34.4%) 3.34 (2.15–5.21) 3.38 (2.17–5.28)
High area 215 (70.0%) 92 (30.0% 2.8 (1.77–4.45) < 0.001 2.82 (1.78–4.49)
Education
Primary or less 400 (73.1%) 147 (26.9%) 1.23 (0.91–1.66) 0.153
High School 365 (78.0%) 103 (22.0%) 1
Higher 221 (79.2%) 58 (20.8%) 0.88 (0.61–1.28)
Socioeconomic status
Poor 240 (75.5%) 78 (24.5%) 1.09 (0.81–1.48) 0.556
Not poor 685 (77.0%) 204 (23%) 1
Marital Status
Married / cohabiting 369 (75.8%) 118 (2.2%) 1.12 (0.84–1.49) 0.523
Divorced 72 (77.4%) 21 (22.6%) 0.88 (0.51–1.53)
Single 521 (76.8%) 157 (23.2%) 1
Widow 25 (67.6%) 12 (32.4%) 1.57 (0.75–3.29)
Illegal drug consumption
Yes 149 (68.3%) 69 (31.7%) 1.64 (1.16–2.32) 0.006 1.65 (1.15–2,37) 0.006
No 838 (77.8%) 239 (22.2%) 1 1
Alcohol consumption
(CAGE score)
Yes 52 (72.2%) 20 (27.8%) 1.28 (0.74–2.22) 0.38
No 534 (75.1%) 177 (24.9%) 1
Ex prison inmate
Yes 49 (80.3%) 12 (19.7%) 0.68 (0.31–1.47) 0.305
No 936 (76.1%) 296 (23.9%) 1
Diabetes Mellitus, as
reported by the patient
Yes 41 (74.5%) 14 (25.5%) 1.12 (0.60–2.08) 0.725
No 944 (76.3%) 294 (23.7%) 1
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facilities in Lima is organized in micronetworks within
districts. There may be characteristics of these micronet-
works in the higher area that do not favor screening,
such as number of health staff dedicated to TB activities
and poorer supervision practices. This should be further
explored in future studies.
The single patient related factor –among those mea-
sured by the study- associated to not being screened was
illegal drug consumption. The screening strategy in this
group (17% of the TB patients in our study reported use
of illegal drugs) should be reinforced. The use of any il-
legal drug is associated with risk behaviors that may in-
crease the likelihood of acquiring or transmitting HIV
infection. In South Africa, fear, low perception of risk and
the wish of being treated first and only for TB as well as
not being offered screening, was associated to not been
screened for HIV [25]. In a similar study in India, uptake
of HIV testing was significantly lower in older age groups
and females [26]. In Cambodia, married patients, those
with a previous HIV screening, a higher level of education
and with more access to a health facility were more likely
to be screened while self-perceived stigma was associated
to not being screened [27]. Peru is a country with a me-
dian TB incidence and a concentrated HIV epidemic, but
co-infection has increased in recent years. Despite the fact
that since 2013, the NTP recommends that every patient
diagnosed with TB have to be screened for HIV, 100%
screening coverage has not yet been reached.
Our findings suggest the need of strengthening the ref-
erence systems between TB and HIV programs. Despite
having a small number of HIV positive patients, we de-
tected a delay between HIV positive result and HIV pro-
gram enrollment and ART initiation, and we did not
find evidence of HIV program enrollment in five pa-
tients. The HIV and TB program in Peru are partially in-
tegrated but care for both infections is provided in
different facilities. Obtaining an appointment at referral
hospitals in Lima, where HIV diagnosis is confirmed and
managed, can take long and that could be contributing
to the delays found [28]. Stigma has been cited in other
settings as a cause that discouraged rapid linkage to care
of recently diagnosed HIV-positive individuals [29].
Prompt linkage to care for early ART initiation is im-
portant to achieve rapid virologic suppression and re-
duce mortality [30, 31]. A better integration of both
programs could reduce barriers [32–34] for timely care
and facilitate the initiation of ART. Decentralizing HIV
care to peripheral health facilities where TB is managed
may facilitate geographical access. Yet, if peripheral facil-
ities are located at the patient’s neighborhoods it may in-
crease stigma and fear of disclosure of HIV diagnosis.
This operational study has some limitations. We did
not obtain the exact reasons for why patients refused
screening or why it was not done among those not opt-
ing out, which impedes a more precise explanation to
our findings. Furthermore, we do not know which would
Table 2 Determinants of not being screened for HIV among 1197 patients with a first episode of smear positive pulmonary
tuberculosis, San Juan de Lurigancho, 2010–2011 (Continued)
Characteristics Screened
N(%)
Not screened
N(%)
Crude OR (95% CI) p Adjusted OR (95%CI) p
TB regimen
Regimen for drug sensitive TB 970 (76.1%) 305 (23.9%) 1
Regimens for drug resistant TB 17 (85.0%) 3 (15%) 0.70 (0.20–2.44) 0.556
Employment
Yes 695 (75.8%) 221 (24.2%) 1 0.646
No 190 (75.7%) 61 (24.3%) 0.99 (0.71–1.40)
Student 102 (79.7%) 26 (20.3%) 0.81 (0.50–1.28)
Study Period
1 261 (78.1%) 73 (21.9%) 1
2 233 (76.9%) 70 (23.1%) 1.13 (0.76–1.67) 0.431
3 258 (75.9%) 82 (24.1%) 1.18 (0.80–1.73)
4 235 (74.0%) 83 (26.0%) 1.37 (0.94–2.01)
Place of birth
Coastal region 611 (76.3%) 190 (23.7%) 1 0.985
Jungle region 138 (75.0%) 46 (25.0%) 0.97 (0.65–1.44)
Andean region 237 (76.7%) 72 (23.3%) 0.98 (0.71–1.35)
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Table 3 Determinants of opting out of HIV screening as compared to not being screened for unknown reasons in 307 smear
positive tuberculosis patients not screened for HIV, San Juan de Lurigancho 2010–2011
Characteristics Opted out of
screening
N (%)
Not screened for
unknown reasons
N (%)
Crude OR
(95% CI)
p Adjusted OR (95%CI) p
Sex
Female 39 (36.2%) 69 (63.8%) 1
Male 79 (39.5%) 121 (60.5%) 1.14 (0.70–1.85) 0.595
Age, in years
18–34 83 (37.7%) 137 (62.27%) 1.04 (0.58–1.84) 0761
35–49 24 (36.9%) 41(63.1%) 1
> 50 10 (45.5%) 12 (54.5%) 1.42 (0.53–3.79)
Weight loss reported by the patient
Yes 94 (36.7%) 162 (63.3%) 0.67 (0.37–1.22) 0.194
No 24 (46,2%) 28 (53.8%) 1
Location of health facility in district area
Lowest area 8 (24.2%) 25 (75.8%) 1 1
Middle area 12 (25.5%) 35 (74.5%) 1.07 (0.38–3.00) 0.022 1.21 (0.42–3.49)
Highest area 63 (46.3%) 73 (53.7%) 2.65 (1.12–6.30) 3.28 (1.32–8.18)
High area 35 (38.0%) 57 (62.0%) 1.92 (0.78–4.72) 2.18 (0.86–5.56)
Education
Primary or less 60 (40.8%) 87 (59.2%) 1.28 (0.76–2.16) 0.627
High School 36 (35%) 67 (65.0%) 1
Higher 22 (37.9%) 36 (62.1%) 1.09 (0.55–2.13)
Marital Status
Married / cohabiting 53 (44.9%) 65 (55.1%) 1.44 (0.88–2.35) 0.219
Divorced 5 (23.8%) 16 (76.2%) 0.56 (0.20–1.62)
Single 56 (35.7%) 101 (64.3%) 1
Widow 4 (33.3%) 8 (66.7%) 0.90 (0.26–3.13)
Illegal drug consumption
Yes 19 (27.5%) 50 (72.5%) 0.54 (0.30–0.98) 0.037 0.43 (0.23–0.80)
No 99 (41.4%) 140 (58.6%) 1
Alcohol consumption (CAGE score)
Yes 7 (35.0%) 13 (65.0%) 0.74 (0.29–1.88) 0.524
No 68 (38.4%) 109 (61.6%) 1
Ex prison inmate
Yes 4 (46.7%) 8 (53.3%) 0.81 (0.24–2.74) 0.726
No 114 (38.5%) 182 (61.5%) 1
Diabetes Mellitus, as reports by the patient
Yes 5 (35.7%) 9 (64.3%) 0.90 (0.29–2.75) 0.849
No 113 (38.4%) 181 (61.6%) 1
TB regimen
Regimen for drug sensitive TB 116 (38.0%) 189 (62.0%) 1
Regimens for drug resistant TB 2 (66.7%) 1 (33.3%) 3.29 (0.29–36.6) 0.315
Employment
Yes 83 (37.6%) 138 (62.4%) 1
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have been the coverage if the study were not conducted.
As we made additional efforts to those of the routine
staff to screen patients for HIV, we probably overesti-
mated the routine coverage. However, the coverage re-
ported by this study, reflects the potential reach of HIV
screening if it is systematically offered to all TB patients.
We did not collect risk factors for HIV infection. If we
had collected risk factors for HIV infection, we could
compare the presence of risk factors among the patients
screened, those that opted out and those that were not
screened for unknown reasons. Opting out of HIV
screening could result from a very low perception of risk
or form fear of a positive result because of risk behavior.
In studies in Ethiopia and South Africa, adults with TB
thought that voluntary counseling and testing could
delay TB treatment and that TB treatment should be
prioritized [35]. Finally, the small number of HIV TB
co-infected patients did not allow a multivariate analysis
to predict HIV infection among TB patients. Among the
strengths of the study was that it included a large num-
ber of TB patients representative of the TB population
in the district.
Conclusions
We found that 76.1% patients recently diagnosed with
TB, were screened for HIV. Patients that reported illegal
drug use were less likely to be screened. Patients with a
recent HIV diagnosis took long to be enrolled in a pro-
gram for the initiation of antiretroviral treatment. This
suggests a suboptimal integration of TB and HIV ser-
vices since TB is managed in primary care centers and
HIV is managed in referral centers such as hospitals.
Most studies on HIV screening among TB patients are
from countries with high HIV prevalence. HIV screening
and management among TB patients in settings with
low HIV prevalence (less than 1%), such as Peru should
be enhanced to reduce mortality from co-infection.
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